Partnerships that move research forward.

BioSymetrics brings patient-level analysis, computational discovery, and experimental validation together with partner expertise to advance defined disease questions.

Partnerships shaped by the question.

Our collaborations bring together patient data, biomarkers, and experimental models across disease discovery, biomarker development, and clinical research.

Parkinson’s disease and CDKL5

BioSymetrics’ analysis of Parkinson’s Progression Markers Initiative data identified three patient subtypes. In May 2026, we announced a collaboration with BrainStorm Therapeutics to connect Parkinson’s subtype analysis with BrainStorm’s patient-derived midbrain organoids. The collaboration also included a LouLou Foundation-funded CDKL5 deficiency disorder program with BrainStorm and academic collaborators.

The planned CDKL5 work moves from zebrafish disease modelling and compound screening to evaluation in patient-derived human brain organoids and complementary zebrafish models. In August 2026, a master collaboration agreement formalized the Parkinson’s work. Its initial scope is to align subtypes with biological mechanisms, prioritize biomarkers and targets, test hypotheses in organoid and in vivo systems, and prepare a partner-ready decision package. The initial data readout is targeted for the first half of 2027.

Alzheimer’s biomarker development

In October 2025, Moleculera Biosciences and BioSymetrics expanded their alliance to develop an Alzheimer’s Early Intervention Inflammatory Biomarker panel. The planned approach pairs Moleculera’s neuroinflammatory biomarkers and personal and family history measures with our Augusta™ platform.

The program aims to identify early indicators of Alzheimer’s progression in asymptomatic individuals and support disease trajectory monitoring.

Rare neurological disease cohorts

In April 2026, BioSymetrics and Geneial signed a non-binding letter of intent to collaborate on cohorts for rare neurological diseases. Geneial brings patient engagement and data infrastructure; we bring data integration, standardization, and subgroup analysis.

The proposed work starts by integrating patient-generated and registry data, then defining patient subgroups and developing cohorts for research and future pharmaceutical partnerships.

Duchenne muscular dystrophy biomarkers

BioSymetrics, Leiden University Medical Center, the University of Florida, and Parent Project Muscular Dystrophy combined clinical and proteomic data from more than 700 longitudinal serum samples across two cohorts. BioSymetrics led the data integration and analysis for the study, published in Nature Communications.

The study reported RGMA, ART3, and ANTXR2 among proteins associated with motor performance and disease progression. These findings may inform prognosis, patient stratification, and clinical trial design.

Could a BioSymetrics partnership support your neurology or rare disease program?

We welcome pharma and biotech partners, research and clinical institutions, patient organizations, and data or model partners with a defined disease question.

Partner with us